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A B S T R A C T
Recent studies have indicated an increasing incidence of melanoma worldwide. Although UV signature mutations
are found rarely in melanoma cells, there is some evidence that intense intermittent exposure to sunlight can induce
melanocyte tumorigenesis, and this is also observed after UV irradiation in some animals. The purpose of this paper is to
review some of the most important mechanisms involved in the pathogenesis of this tumor. Genetic studies showed the fa-
miliar melanoma is linked to the mutation or deletion of the suppressor gene CDKN2A, and perhaps to CDK4. Studies
showed that BRAF mutation is frequent in primary and metastatic melanoma cells but also in naevocytic nevi. This mu-
tation activates the RAF/MEK pathway. Exposure to UV radiation induces immunosuppression. Recent investigations
showed that chemokines, angiogenesis, metalloproteinases can play a role in the mechanism of metastasis. In spite of
these advances the initiating events are still not completely understood. In conclusion, the pathogenesis of melanoma is
very complex because numerous genetic and epigenetic factors are implicated in its development and progression, but
some of the showed mechanisms can be targets for new therapies.
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Introduction
Melanoma as a »fatal black tumor with metastasis«
had been already described in the Corpus Hippocraticus1.
Recent epidemiologic studies have found an increasing
incidence of melanoma at an alarming rate in several
parts of the world2–5. The tumor develops from melano-
cytes in the skin, but can arise also in the mucous mem-
branes, uveal tract of eyes, and leptomeninges. The fac-
tors implicated in the fast rise in the incidence of mela-
noma are incompletely understood. In part this can be
explained by the change in life style, changes in clothing,
vacational and weekend sunbathing, longevity, strato-
spheric ozone depletion6–7. The melanoma etiology is
multifactorial: both genetic factors (familial melanoma,
xeroderma pigmentosum, fair skin) and environmental
factors such as sunlight (especially the UV radiation)
contribute to its inception and evolution8. The role of
other, non sunlight risk factors, like exposure to ionizing
radiation, exposure to chemicals used in some occupa-
tions have been also related to melanoma, but possible
interactions with genetic factors and UV irradiation is to
take in to account9–11. Immunity can also be involved.
In recent years, there has been much concern for hu-
mans regarding solar or artificial UVA in the induction of
melanoma12. Although UVB signature mutations C-T
and CC-TT transition13 are found rarely in melanoma
cells, there is some evidence that intense intermittent ex-
posure to sunlight can induce melanocytes tumorigene-
sis, and this is also observed after UV irradiation in some
animals13–15. The purpose of this paper is to review the
knowledge about the mechanism of initiation and pro-
gression of melanoma.
Hallmarks of Malignant Tumors
During the last decades the understanding of the
pathogenesis of tumors has increased considerably but
some aspects are still not fully understood. Cancer cells
develop from »normal« cells through the accumulation of
genetic alterations, which finally leads to the malignant
phenotype.
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Hanahan and Weinberg have reviewed the most im-
portant alteration in a cell leading to malignant transfor-
mation and proliferation16:
¿ self-sufficiency in growth signals (growth factors,
their receptor up-regulation, or growth signaling
pathways like ras – raf, MAP cascade);
¿ insensitivity to antigrowth signals (pRb lost by mu-
tation of its gene or sequestrated by viral oncogens);
¿ acquisition of resistance toward apoptosis (defect in
activation of FAS death signaling circuit or a muta-
tion in p53 in response to damage of DNA via signal
for proapoptotic Bax);
¿ acquisition of limitless replicative potential (upre-
gulation of telomerases with maintenance of telo-
mere length, circumvention of cellular senescence);
¿ sustained angiogenesis;
¿ tissue invasion and metastasis.
The stepwise progression is possible if there is a ge-
nome instability16. Below we will underscore these as-
pects in melanoma.
UV Effects
It is well established that outdoor or indoor exposure
to UV radiation is associated with the development of
skin cancer: basal cell carcinoma and squamous cell
carcinoma17. The tumor appears in sun-exposed areas
(head, neck, upper limbs), mostly in people with fair
skin, frequently on photoaged skin and with actinic kera-
toses. Acute and chronic UV exposure to UVB (290–320
nm) causes direct DNA damage. DNA absorbs UVB en-
ergy by double bound on adjacent pyrimidine bases, thy-
mine (T) and or cytosine (C) on the same strand, forming
a four-member cyclobutane ring and pyrimidine 6,4 pyri-
midone photoproducts. There is C to T transition or CC
to TT double base mutation18. These changes on p53 are
fingerprints or signature mutations of UVB photocar-
cinogenesis19,20. Experiments in hairless mice and in
xyphophorus hybrid fish confirmed the mutagenic effects
of UVB21–23.
For melanoma it is not so simple to link it to sunlight.
Epidemiological studies showed that melanoma, unlike
other skin cancers, is associated with an intense inter-
mittent exposure to sunshine (trunk and legs), or use of
tanning lamps, especially in childhood12,24. A recent study
showed a significant risk (p<0.05) for melanoma among
individuals who used tanning beds in comparison with
those who never used them25. For long time UVB was be-
lieved to be the »bad UVR« and UVA the safe. Experi-
ments in animals demonstrated that the relevant carcin-
ogen radiation, in melanoma, may be UVA, which causes
oxidative damage in the cells14,15. Solar UVA (320–400
nm) makes up approximately 90–95% of UV rays that
reach the earth’s surface. Their energy is small; however,
they penetrate deeper into the skin. A growing body of
evidence indicates that UVA, even if absorbed weakly by
DNA, causes skin aging, and generates a variety of reac-
tive oxygen species (ROS) such as hydrogen peroxide,
superoxide, peroxinitrite, singlet oxygen i.e. an oxidative
stress26. The epidermis contains antioxidant enzymes
such as catalase, glutathione peroxidase but intense UV
can overwhelm their effects. ROS indirectly damages
DNA, forming purine oxidative (mainly guanine) photo-
products such as 8-oxo-7,8-dihydro-2’deoxy-guanosine,
G-T transitions and strand breaks. These alterations
were demonstrated in experiments on animals and hu-
man fibroblasts27–30. Moreover, ROS can facilitate meta-
stases damaging the endothelial cells.
UVA inducing matrix metalloproteinases, via AP-1
and NF-kB, increases the aggressivity of the skin cancer.
So, UVA radiation, apart of inflammation, and immuno-
suppression can also induce photocarcinogenesis26.
Gene Mutations
The majority of melanomas arises »de novo« from
melanocytes, which function is the synthesis of melanin,
its storage, and transfer to keratinocytes. Some melano-
mas arise from nevi, especially from dysplastic and giant
congenital nevi. There are four clinic-histological types
of melanoma: the most common is the superficial spread-
ing melanoma, then nodular melanoma, lentigo maligna
melanoma and acral lentiginous melanoma31. So it seems
unlikely that only one mechanism or few genes can have
a role in the origin and progression of melanoma cells.
The pathogenesis of melanoma is complex because
numerous genetic, epigenetic factors (hyper- or hypome-
tilation of DNA, acetylation), and environmental factors
are implicated in its development and progression32–34.
The mutation, deletion, amplification, translocation or
methylation of suppressor genes or activation of proto-
oncogenes are of paramount importance in the mutagen-
esis. The mutations of oncogenes are dominant: change
in one allele has a determinate effect and can stimulate
the growth or proliferation of the cell. Clark et al. pro-
posed that the development of melanoma (melanomage-
nesis) is commonly stepwise: nevus, dysplasia, melanoma
with radial growth phase, vertical growth which is asso-
ciated with metastasis35. For the clinician and patholo-
gist it is important weather melanoma is in the radial-
-non metastatic phase, or in the vertical growth phase,
when metastases are common36.
In 1820, Norris already wrote that black tumors and
moles may be hereditary37. Numerous epidemiological
and genetic studies showed the familial melanoma, which
represents 8–12% of all melanomas38, is linked to the
muation or deletion of the suppressor gene CDKN2A,
and occasionally with mutation of the protooncogene
CDK439,40. In familial melanoma patients there is com-
monly an aberrant regulation of the cell cycle by cyclins
with cyclin dependent kinases: they carry a germ line
mutation in the locus cyclin dependent kinase inhibitor
2A gene (CDKN 2A) on the chromosome 9p21. It encodes
two suppressor proteins p16 (inhibitor kinase 4A-INK4A)
and p14 or Arf (alternative reading frame). The a read-
ing frame encodes p16 whose function is to inhibit the
complexing ciklin D/CDK4 and CDK6 i.e. enzymes that
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phosphorilate the retinoblastoma protein (pRB) and so
drive the cell division cycle. pRB phosphorilation conse-
quently releases E2F, which among others, drives the G1
in S phase of the cell cycle41–44. Recently, Wang et al.
found that protein E2F1 has also a suppressor function
through p53 or p7345. Mutation of CDKN2A is found in
10–30% of the cases in familial melanoma. The mutation
or silencing of p16 has been found also in sporadic cases
of melanoma, some with C-T transitions, and also to-
gether with mutation of the oncogene N RAS46.
Patients with CDKN2A mutation can present multi-
ple melanomas. Mutation or loss of CDKN 2A occurs
rarely also in actinic keratoses, skin carcinomas, lung
carcinoma, breast carcinoma, and other tumors.
The CDKN2A b reading frame encodes p14 (ARF)
whose function is to sequester the Mdm2 protein, a nega-
tive regulator of p53 mediating its degradation in the
proteasome. Loss of ARF decreases p53 activity and
apoptosis of mutated cells47. Recent experiments demon-
strated in mice models that p14 is a suppressor and can
induce even senescence in melanocytes activated by on-
cogens48,49. So, mutation of CDKN2A results in loss of
pRB, p53 control of cell regulation and evasion of senes-
cence.
The development of melanoma is linked also to the
skin color. Melanoma occurs in whites tenfold more fre-
quently than in blacks, while it is rare in albinos. This
correlation depends mostly on the amount of melanin.
So, fair skinned people (skin types I and II) with blond or
red hair are more predisposed to melanoma. This is asso-
ciated with the function of the melanocortin 1-receptor
gene (MC1R), located on chromosome 16q24. The gene is
highly polymorph and influences sun-sensitivity50,51. It
encodes the transmembrane G protein receptor. aMela-
nocyte–stimulating hormone (aMSH) the clivage prod-
uct of pro-opiomelanocortin (POMC) secerned by the pi-
tuitary, and ACTH, bound and activate the receptor
which increase cAMP and so the activity of tyrosinase.
Relevantly, these hormones can be also synthesized by
the keratinocytes52. aMSH increases the production of
the dark eumelanin and yellow pheomelanin rich in
cystein. Studies in families with melanoma predisposi-
tion (p16 defect) showed that components carrying a
variation of MC1R developed earlier melanoma53. Micro-
phtalmia associated transcription factor (MITF) is a gene
on chromosome 3p14, relevant in transcription of genes
for melanin synthesis. Recent studies demonstrated that
it is an oncogene, promoting melanocytes cell cycle pro-
gression54.
The gene CDK4 (chromosome 12 p14) mutation, whose
protein is a kinase, has also been found in some mela-
noma families, and this lead to cycle progression55. Ex-
periments in transgenic mice expressing a mutant CDK4
have shown that the inactivation of retinoblastoma/p16
pathway, leads to the development of melanoma56. Mela-
noma can develop also in patients suffering from heredi-
tary retinoblastoma i.e, with germline mutation of Rb1
gene (13 q14), and in patients with mutations or amplifi-
cations of CDK457.
Patients with xeroderma pigmentosum, in which nu-
cleotide excision repair (NER) is defective, are character-
ized by a high sensitivity to sunlight, with sunburns, and
freckling. The UVR induced DNA damage is not recog-
nized or incorrectly repaired, it remains mutated and
this leads to an early development of precancerous le-
sions, nonmelanoma skin cancer, and melanoma20. Inter-
estingly, patients with xeroderma pigmentosum, who de-
velop melanoma have frequently mutated p53, a rarely
mutate gene in sporadic melanoma58. Moreover, trans-
genic mice without these genes have increased photosen-
sitivity and are prone to develop skin tumors59.
Another DNA mutation found in melanoma, is the
protooncogene BRAF (chromosome 7q34) which encodes
a cytoplasmatic serine/threonine kinase in the ras path-
way. BRAF mutation is present in approximately 60% of
the cases, and is the most frequently mutated gene in
this tumor, especially on the non sun exposed areas, or
better on the intermittent exposed areas (trunk, legs).
BRAF activates by phosphorilation other protein kin-
ases: MEK-ERK (which enter the nucleus)-MAP cascade.
The mutation hits the exone 15 with a substitution of
valine with gluthamic acid at position 600 (val 600 glu)60,61.
So, the substitution of only one aminoacid leads to muta-
tion. Studies showed that BRAF mutations are frequent
in primary and metastatic melanoma cells, but also in
nevocytic nevi62. This mutation activates the RAF/ MEK
pathway. Because of BRAF frequent mutation in nevi, it
influences more the proliferation than tumorigenesis,
and probably is an early event that must be accompanied
by other gene alterations63. A recent international study
by Curtin et al. on 126 cases of melanoma has demon-
strated that in mucosal and acral melanomas there is
commonly a loss of the CDKN2A locus, while on the
trunk is more frequent BRAF mutation64.
Among the many genes found to be mutated in mela-
noma, there is also the suppressor gene phosphatase and
tensin (PTEN), which is located on chromosome 10q23
and encodes a phosphatase that regulates the extrace-
llular growth signals through the lipid phospha-tidyli-
nositolphosphatase (PIP3). PTEN is inactivated by mu-
tation, reduced expression or deletion in 25–50% of non-fa-
milial melanoma. The mutation activates through PIP3
AKT and so promotes the cycle progression and inhibits
apoptosis62. So, PTEN seems to be a regulator of apo-
ptosis, cell proliferation, and cell adhesion. There may be
a later mutation, and recently it was found an epigenetic
silencing of the gene by promoter inactivation65. Fur-
thermore, PTEN is important for the integrity of the
chromosomes, as its mutation is associated with frequent
chromosome translocation. Mutation of BRAF and PTEN
occurs frequently together63.
Mutations in ras genes (1p13) are present in about
20% of human melanomas and are found also in nevi.
Commonly the isoform N-Ras is present. This mutation
is observed frequently in melanoma from sun-exposed
areas, and in congenital nevi. Studies demonstrated that
N-RAS and BRAF mutations are not present in the same
melanoma66.
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In human malignant tumors, the most frequently mu-
tated gene is the suppressor p53 located on chromosome
17p13. Its protein product is a transcriptional factor that
activates the transcription of numerous genes67. P53 has
a pivotal role in preserving genetic integrity: It is impli-
cated in DNA repair mechanisms, apoptosis (through
Bax), and cell cycle control through its effector p21. In-
vestigations in melanomas showed that p53 mutations
are rather rarely detected (about 10%), mostly in a later
phase, and even lesser in nevi66 but the protein can be
over expressed especially in sites exposed to sunlight. Re-
cently, Cui and al. demonstrated that UV irradiation of
mouse and human skin generates an increase of p53,
that stimulates the synthesis of a MSH in keratinocytes
and melanocytes and so the pigmentation68. The rele-
vance of BRAF and p53 mutation in the origin of nevi
and melanoma demonstrated recently experiments per-
formed in zebrafish: the introduction of mutated BRAF
in one-cell stage of the zebrafish led to the development
of nevi. If the mutated BRAF was injected in p53 defi-
cient fish, fishes developed melanoma69.
Last years, studies of melanoma in mice led to the dis-
covery of a gene relevant for metastasis, and this allowed
todetermine the gene in man. The gene, NEDD9, is lo-
cated on chromosome 6p, and is important for molecules
implicated in cell adhesion70. New techniques permitted
to found in melanoma the presence of stem cells, which
obviously have an outstanding role in the course of the
disease71.
Role of Telomerase and
Immunosuppression
Investigation showed that telomerases are highly ex-
pressed in more than 85% of tumors, but repressed in
normal cells72. Telomerases are responsible for man-
taining telomeres length on the end of the chromosomes.
Telomere caps preserve chromosomes from degradation
and from genomic instability i.e. abnormal recombina-
tion during replication prolonging the life span of the
cells. With the progressive loss of telomeres, and shorten-
ing of the chromosomes with every successive cycle, the
chromosomes reach a critical length (about half of the
originally length) at which cell division ceases, senes-
cence begins, and the cell ultimately undergoes apoptosis
or cell death20. Studies demonstrated that telomerases
are significantly more expressed in melanoma than in
nevi73. This unambiguously confirms the relevance of the
telomerases expression in tumors.
It is well known that defects in the immune response
and immunosuppressive therapy can facilitate the devel-
opment of tumors. Haniszko et al. demonstrated that UV
irradiation of the skin suppresses contact sensitivity to
DNCB, a strong antigen74. In the last decades an increas-
ing amount of evidence suggests that UVR beside induc-
tion of tumors causes also immune suppression. Kripke
found that UVR induced skin tumors were highly antige-
nic and rejected when transplantated in syngenic mice75.
However, the tumors grew rapidly if the mice were ex-
posed to UVR. Probably this was linked to a loss of im-
munity, because the effect was transferable to other ani-
mals with T lymphocytes. These observations lead to the
hypothesis that UVR suppressed the immune system
both locally and systemically. So UVR inducing immuno-
suppression interferes with immunological mechanism
of tumor immunosurveillance76–78. First it was believed
that only UVB could induce DNA damage, and so trigger
immune suppression. Recent works demonstrated that
also UVA can produce the same effect by altering the an-
tigen presentation through depletion of Langerhans cells
from the epidermis, induction of regulatory T cells (treg-
-formerly suppressor T Cell), production of IL-10, TNF
a. The result is down-regulation of the cellular immune
response such as induction and elicitation of contact hy-
persensitivity, and also an inhibition of NK cells activity,
while the humoral part of the immune response is not
altered80.
Immunosuppression induced by UV can arise from
damage of DNA, presence of the urocanic acid in the stra-
tum corneum, which after exposure to UVR isomerizes
in the cis configuration that has an immunosuppressive
action or UVR leads to the formation of free radicals and
membrane lipide peroxydation causing immune suppres-
sion. UV irradiation of keratinocytes releases neuropep-
tides and aMSH, which has immunomodulatory effects.
Finally UVR can induce immunosuppression through
transformation of provitamin in vitamin D20,81. Despite
the long story of immunotherapy in advanced stages of
melanoma, the results are scantily82.
Recent investigations showed that growth factors,
chemokines, angiogenesis (in which VEGF, FGF, and Il-8
are implicated), matrix metalloproteinases, could play a
role in the mechanism of melanoma progression and
metastasis83–86. In spite of these advances the initiating
events are still not completely understood.
Conclusion
This brief review of the genetic and immunologic
mechanisms of melanomagenesis underscores the rele-
vance of UV irradiation, mutation or deletion of some
oncogenes and suppressor genes, immune suppression,
and telomerase activity in the initiation and progression
of the tumor. It seems that of paramount importance are
mutations that lead to clonal expansion (RAS, BRAF),
changes that disconnect senescence (activation of telo-
merase), and evasion of apoptosis. The knowledge of
such mechanism will be of significance for a new molecu-
lar classification of melanoma, has importance in better
prognosing the outcome, and permits the development of
new molecular target therapy for tumors.
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GENETSKI I MOLEKULARNI MEHANIZMI U NASTANKU MELANOMA
S A @ E T A K
Novija istra`ivanja ukazuju na porast broja melanoma {irom svijeta. Unato~ tome {to se signaturne mutacije rijetko
opa`aju u melanomskim stanicama, postoje dokazi da intenzivno i intermitetno izlaganje UV zrakama mo`e prouzro~iti
malignu transformaciju melanocita, na {to upu}uju eksperimenti na `ivotinjama izlo`enim UV zrakama. U ovom smo
se radu osvrnuli na va`nije mehanizme uklju~ene u patogenezu ovog tumora. Genetske studije obiteljskog melanoma
ukazale su na udru`enost s mutacijama ili delecijom supresornog gena CDKN 2A, a vjerojatno i gena CDK4. Isto tako
utvr|ena je ~e{}a pojava mutacije BRAF-a u primarnim i metastatskim melanomima, a tako|er u pigmentnim made-
`ima. Ta mutacija aktivira RAS-MEK signalni put. Izlaganje UV zra~enju uzrokuje i imunosupresiju. Novija istra`i-
vanja su pokazala da kemokini, angiogeneza i metaloproteinaze mogu imati ulogu u nastanku metastaza melanoma.
Unato~ svim postignu}ima po~etni doga|aji jo{ nisu potpuno razja{njeni. U zaklju~ku treba istaknuti da je patogeneza
melanoma vrlo slo`ena, te da u razvoju melanoma zna~ajnu ulogu imaju genetski, epigenetski i ~imbenici okoli{a. Neki
od spomenutih mehanizama mogu biti cilj novih terapija.
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